Bavarian Nordic beats Q3 revenue expectations on travel health strength (updated)
UPDATE 1-Bavarian Nordic beats Q3 revenue expectations on travel health strength Adds CFO comments in paragraph 2, bullet point 3; US demand for rabies vaccine in bullet point 2
Nov 13 (Reuters) - Danish vaccine maker Bavarian Nordic BAVA.CO reported better-than-expected third-quarter revenue on Friday, boosted by a continued strong performance in its travel health business.
CFO Henrik Juuel told Reuters Bavarian does not see any signs that the market for the rabies vaccine - one of its biggest revenue drivers - will decline anytime soon.
Travel health revenue rose 22%, beating consensus by 13%, driven by the continued strong sales of its rabies vaccines RabAvert/Rabipur and supported by the continued launch of its chikungunya vaccine Vimkunya
The US rabies vaccine market grew by 36% in the first nine months versus the prior year
Juuel said the awareness around the disease was encouraging more people to seek vaccination
Third-quarter revenue of 1.81 billion Danish crowns ($267.81 million) beat analysts' average consensus estimate of 1.69 billion
The company reiterated the full-year guidance it upgraded in October
($1 = 6.7585 Danish crowns)
(Reporting by Elviira Luoma, editing by Matt Scuffham and Anna Pruchnicka)
((elviira.luoma@thomsonreuters.com; +48 58 769 66 46;))
Recent news on Bavarian Nordic A/S
See all newsBavarian Nordic beats Q3 revenue expectations on travel health strength (updated)
Bavarian Nordic beats Q3 revenue expectations
Brief: Bavarian Nordic Launches Next Tranche Of Share Buy-Back Program
Brief: Bavarian Nordic CFO Henrik Juuel To Step Down
Denmark's Vaccine maker Bavarian Nordic Q3 EBITDA margin rises, upgrades FY outlook